Back to top
more

Agenus (AGEN)

(Real Time Quote from BATS)

$5.33 USD

5.33
323,833

-0.07 (-1.30%)

Updated Apr 18, 2024 10:34 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 4.72% and 31.47%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Milestone Pharma (MIST) Down on Regulatory Update for Etripamil

by Zacks Equity Research

Milestone Pharma (MIST) plunges 31% following an RTF letter from the FDA due to insufficient data to begin a substantive review of the regulatory filing for etripamil nasal spray to treat PSVT.

Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag

by Zacks Equity Research

Merck (MRK) and Daiichi Sankyo's regulatory filing for HER3-DXd gets the FDA's priority review grant for the treatment of adult patients with lung cancer. A final decision is expected on Jun 26, 2024.

GSK, Hansoh Ink Deal to Develop Lung Cancer ADC Candidate

by Zacks Equity Research

GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.

Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data

by Zacks Equity Research

Immunovant (IMVT) announces positive initial data from the mid-stage study of batoclimab in patients with Graves' disease. The stock gains 12% in the after-market hours, following the news.

CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%

by Zacks Equity Research

CARA discontinues the clinical program of oral difelikefalin for pruritus associated with atopic dermatitis following the failure of dose-finding Part A of the late-stage study. Stock plunges 49%.

Reneo (RPHM) Plummets 83% on Failure of Metabolic Disorder Study

by Zacks Equity Research

Reneo (RPHM) loses 83% following the failure of the mid-stage pivotal study of its only pipeline candidate, mavodelpar, to treat primary mitochondrial myopathies in adults. It cuts the workforce by 70%.

Acadia (ACAD) Rises 35% on Positive Patent Ruling for Nuplazid

by Zacks Equity Research

Acadia (ACAD) announces a ruling from the U.S. District Court in Delaware, strongly in favor of the company for its patent for Nuplazid. The stock surges 35% in response.

Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up

by Zacks Equity Research

Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.

Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why

by Zacks Equity Research

Biomea Fusion (BMEA) rises 41% in a month on the back of positive investor expectations regarding the clinical development of its lead candidate, BMF-219, for the type II diabetes indication.

Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study

by Zacks Equity Research

Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.

Dr. Reddy's (RDY), COYA Ink Deal to Develop COYA 302 for ALS

by Zacks Equity Research

Dr. Reddy's (RDY) enters into a licensing agreement with Coya Therapeutics to develop and commercialize the latter's ALS investigational combination therapy, COYA 302.

Bristol Myers' (BMY) Opdivo sBLA Gets FDA's Priority Review

by Zacks Equity Research

Bristol Myers (BMY) announces that the FDA has accepted its sBLA for Opdivo to treat first-line adult patients with unresectable or metastatic bladder cancer under priority review.

Acadia (ACAD) Begins Study on ACP-101 for Hyperphagia in PWS

by Zacks Equity Research

Acadia (ACAD) begins late-stage development of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome.

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

by Zacks Equity Research

BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.

Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study (Revised)

by Zacks Equity Research

Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.

Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study

by Zacks Equity Research

Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.

Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance

by Zacks Equity Research

Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.

Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson

by Zacks Equity Research

Can-Fite (CANF) stock up 7% as the liver cancer patient achieves a complete response and overall survival of 6.9 years upon continued treatment with namodenoson in a phase II study.

Anavex (AVXL) Up 12% on Regulatory Update for Alzheimer's Drug

by Zacks Equity Research

Anavex (AVXL) announces an encouraging regulatory update for its investigational candidate, blarcamesine, in the treatment of Alzheimer's disease. The stock rises 12%.

Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why

by Zacks Equity Research

Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.

Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7%

by Zacks Equity Research

Agenus (AGEN) to halt all other developmental programs to focus on its BOT/BAL program. The company plans to cut its workforce by 25%.

Compared to Estimates, Agenus (AGEN) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Agenus (AGEN) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Travere (TVTX) delivered earnings and revenue surprises of 2.59% and 10.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Agenus (AGEN) delivered earnings and revenue surprises of -4.76% and 2.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?